Caricamento...
DCVax®-L—Developed by Northwest Biotherapeutics
Dendritic cell (DC) immunotherapy is emerging as a potential addition to the standard of care in the treatment of glioblastoma multiforme (GBM). In the last decade or so various research groups have conducted phase I and II trials of DC-immunotherapy on patients with newly diagnosed (ND) and recurre...
Salvato in:
| Pubblicato in: | Hum Vaccin Immunother |
|---|---|
| Autori principali: | , |
| Natura: | Artigo |
| Lingua: | Inglês |
| Pubblicazione: |
Taylor & Francis
2014
|
| Soggetti: | |
| Accesso online: | https://ncbi.nlm.nih.gov/pmc/articles/PMC4514134/ https://ncbi.nlm.nih.gov/pubmed/25483653 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.4161/hv.29276 |
| Tags: |
Aggiungi Tag
Nessun Tag, puoi essere il primo ad aggiungerne! !
|